Disease modification in OA — will we ever get there?

L. Stefan Lohmander; Ewa M. Roos

doi:10.1038/s41584-019-0174-1

Disease modification in OA — will we ever get there?

L. Stefan Lohmander, Ewa M. Roos

University of Southern Denmark

Forskningsoutput: Tidskriftsbidrag › Debate/Note/Editorial › Peer review

Sammanfattning

No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

Originalspråk	engelska
Tidskrift	Nature Reviews Rheumatology
DOI	https://doi.org/10.1038/s41584-019-0174-1
Status	Published - 2019 feb. 7

Ämnesklassifikation (UKÄ)

Reumatologi och inflammation

Tillgång till dokument

10.1038/s41584-019-0174-1

Citera det här

@article{62ac21d7beb843c0a5bebffd91c0ac69,

title = "Disease modification in OA — will we ever get there?",

abstract = "No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.",

author = "Lohmander, {L. Stefan} and Roos, {Ewa M.}",

year = "2019",

month = feb,

day = "7",

doi = "10.1038/s41584-019-0174-1",

language = "English",

journal = "Nature Reviews Rheumatology",